Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: ribociclib (LEE011)|DRUG: Exemestane|DRUG: Everolimus (RAD001)
Sponsor: Novartis Pharmaceuticals